SHANGHAI, Aug. 27, 2018 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, announced appointment of Dr. Hong Ma as Senior Vice President, Clinical Development. Dr. Ma will be responsible for CARsgen clinical strategy, leading clinical development and medical team overseas.